Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26272100 | 1.00 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2KDM4EALOX15TSHR | |
| SCHEMBL27303608 | 1.00 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2KDM4EALOX15TSHR | |
| SCHEMBL7885790 | 0.89 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL12213864 | 0.89 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL5538919 | 0.89 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL13978586 | 0.89 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL3930061 | 0.89 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL26270951 | 0.88 | HSD17B10 (0.54) | HSD17B10SMN1; SMN2KDM4EALOX15TSHR | |
| SCHEMBL27330598 | 0.88 | HSD17B10 (0.54) | HSD17B10SMN1; SMN2KDM4EALOX15TSHR | |
| SCHEMBL24368139 | 0.87 | HSD17B10 (0.91) | HSD17B10SMN1; SMN2KDM4EALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112612-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | HSD17B10 1624/4885SMN1; SMN2 4637/4885KDM4E 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.